A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G- MARV-GP Vaccine in Adults in Good General Health

Infectious Diseases

The GW Vaccine Research Unit is recruiting volunteers for a study to examine a new vaccine for the prevention of the Marburg virus.

Key Facts about the Marburg Virus:

The Marburg virus causes a severe hemorrhagic fever that has a high fatality rate.
Marburg Virus Disease occurs in sporadic outbreaks primarily in Sub-Saharan Africa.
Currently, there are no approved treatments for the disease.

This study requires participants to attend 9 in-clinic visits over 7 months. To participate in this study, you will receive a vaccine. Those who are eligible and attend the in-clinic visits will receive $75.00 per visit to compensate for time and travel.

Seeking volunteers:

Ages 18 - 50
Lives in the Washington D.C. metropolitan area
In good general health

Fill out interest survey here.

Principal Investigator(s)

David Diemert, MD

Contact Phone Number

202-994-1599

Request Information

First Name

Last Name

Email Address

Confirm email

Phone Number

Address

Address 2

City/Town

State/Province

ZIP/Postal Code

Comments / Questions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.